A Study to Evaluate Efficacy and Safety of Light Dose in Subjects With PWS Treated With Hemoporfin + PDT
Status:
Not yet recruiting
Trial end date:
2024-09-01
Target enrollment:
Participant gender:
Summary
This is a multi-center, randomized, evaluator-blinded, vehicle-controlled, and sequential
group Phase 2 study. Eligible subjects aged 18 to 65 years old with PWS of face and/or neck
area will receive Hemoporfin PDT or vehicle PDT in 8-week cycles at fixed drug dose and
different light fluence.